Attovia Therapeutics reported second-quarter 2026 financial results and provided a corporate update. The company generated $0.5 million in collaboration revenue and incurred a net loss of $20.7 million, with R&D expenses rising to $18.9 million. Cash and equivalents stood at $115.1 million as of June 30, 2026. Attovia highlighted preliminary clinical proof of concept for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis, with complete Phase 1b data expected in Q4 2026. Global Phase 2 studies for ATTO-1310 are planned for the first half of 2027, while Phase 1 initiation for ATTO-2306 and ATTO-1091 is also targeted for early 2027. The company completed an upsized IPO with gross proceeds of $332.4 million, extending its cash runway into 2030. Attovia Therapeutics operates in the biopharmaceutical industry, developing next-generation biotherapeutics for immune-mediated diseases.